Micell Technologies (Durham, NC) is releasing its flagship product, the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System, in the European market. The stent is designed to release rapamycin to prevent restenosis, but unlike similar stents the crystalline drug stays within the nearby tissue for months after the coating and polymer surrounding the cobalt chromium metal stent have been absorbed.
The technology relies on Micell’s patented supercritical fluid technology that allows the drug together with the polymer to stick to the metal stent. The underlying stent is actually the Genius MAGIC made by Eurocor that features a particularly thin strut design.
More from the announcement:
The rapidly absorbable coating of the MiStent SES is intended to precisely and consistently provide for local drug delivery and limit the duration of polymer exposure, thereby potentially reducing the safety risks associated with current commercially available drug-eluting stents. The MiStent SES includes a proprietary stent coating that contains crystalline drug (sirolimus) and an absorbable polymer. The coating provides controlled and sustained release of therapeutic levels of drug as the polymer disperses from the stent into the adjacent tissue. These properties are intended to enhance safety as compared to conventional permanent polymer drug-eluting stents.
Product page: MiStent SES…